阿尔茨海默病中的视空间障碍和静止状态网络相关性:系统性审查
Ho Yan Lai1, Andi Tri Supratno Musrah2, Kah Hui Yap3
1Department of Psychology, Faculty of Behavioral Sciences, HELP University, Selangor, Malaysia.
Behavioural brain research
|August 7, 2025
概括
阿尔茨海默氏症亚型显示出明显的脑网络干扰,影响视觉空间技能. 静态fMRI揭示了这些网络变化,为诊断和治疗提供了潜在的生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 认知神经学 认知神经学
背景情况:
- 阿尔茨海默氏症 (AD) 在亚型中呈现出各种视觉空间障碍,如记忆障碍AD和后皮层缩 (PCA).
- 休息状态功能性MRI (rs-fMRI) 表明AD中大脑网络受损,但与视觉空间缺陷的联系尚未完全理解.
研究的目的:
- 为了研究不同阿尔茨海默病亚型的视觉空间缺陷.
- 通过 rs-fMRI 来识别这些亚型中受影响的特定大脑网络.
- 为AD相关的视觉空间障碍提供潜在的临床干预信息.
主要方法:
- 一项对6项研究的系统综述,比较了AD患者和健康对照者的视觉空间性能和rs-fMRI连接性.
- 对行为任务的效果大小 (Bonett's δ) 和对成像临床关联的相关系数 (r) 的合成.
主要成果:
- 在AD中观察到显著的视觉空间缺陷,amnestic AD显示中度至大效果大小,PCA显示严重损伤.
- Rs-fMRI检测出背脊顶脊,默认模式 (DMN) 和小脑皮层网络中的连接中断.
- 中等相关性 (r=0.33-0.44) 将DMN和小脑连接性损失与雷-奥斯特里斯复杂图形测试中的表现较差联系起来.
结论:
- 独特的网络功能障碍模式是AD亚型的特征,PCA显示后部网络问题和涉及DMN和小脑退化的amnestic AD.
- Rs-fMRI为AD中视觉空间缺陷的神经基础提供了关键的见解.
- 这些发现表明,基于rs-fMRI的生物标志物可能用于亚型特定的AD诊断和有针对性的干预措施.
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262


